All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to steering committee member Mohamad Mohty, Hôpital Saint-Antoine, Paris, FR. We asked, What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?
What's the latest in treatment of steroid-refractory acute GvHD at ASH 2021?
In this podcast, Mohty highlights the latest advances in the field of steroid-refractory acute GvHD and emphasizes the importance of prevention, commenting on anti-thymocyte globulin (ATG), allogeneic hematopoietic stem cell transplant (allo-HSCT), and posttransplant cyclophosphamide. Mohty also mentions the HERACLES trial (NCT03225937) and the use of the JAK inhibitor ruxolitinib.
Comparison of PTCy with antithymocyte globulin in patients with AML in the first CR undergoing allo-HSCT
Eolia Brissot and colleagues retrospectively analyzed a population of patients with acute myeloid leukemia following allo-HSCT using 10/10 MUD...
ASH 2018 | Ruxolitinib plus corticosteroids in patients with steroid-refractory acute graft-versus-host disease – The REACH1 trial
Jagasia M. et al. Results from REACH1, a Single-Arm Phase II Study of Ruxolitinib in Combination with Corticosteroids...
Subscribe to get the best content related to GvHD delivered to your inbox